Tumour necrosis factor-alpha (TNF-α) inhibitors have been introduced in the treatment of refractory sarcoidosis. These biologics may reactivate latent tuberculosis infection (LTBI). Despite its known limitations, the tuberculin skin test (TST) is currently used for the diagnosis of LTBI in Danish sarcoidosis patients. We report the results of a screening using the interferon-gamma release assay (IGRA) QuantiFERON TB Gold (QFN) for the diagnosis of LTBI. We aimed to assess whether the QFN is reliable for diagnosing LTBI among sarcoidosis patients and if results are influenced by disease activity or immunosuppressive treatment.
Scandinavian Journal of Infectious Diseases, 2011, Vol 43, Issue 9, p. 728-35
Adult; Biological Agents; Clinical Laboratory Techniques; Humans; Immunoassay; Immunologic Factors; Male; Mass Screening; Middle Aged; Predictive Value of Tests; Prospective Studies; Sarcoidosis; Tuberculosis; Tumor Necrosis Factor-alpha; Evaluation Studies; Journal Article